While one study classifies this mutation as a poor prognostic factor, the other ones present no significant impact on the clinical outcome or prognostic features [39,40,42,46], and still others indicate the synergizing effect of PI3K-RAS with KMT2A rearrangements that reduces leukemia latency [22,47]. The gene discussed is KMT2A; the disease is leukemia.